Profile data is unavailable for this security.
About the company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
- Revenue in USD (TTM)0.00
- Net income in USD-31.04m
- Incorporated2018
- Employees31.00
- LocationIN8BIO, Inc.Empire State Building350 5Th Avenue, Suite 5330NEW YORK 10118United StatesUSA
- Phone+1 (646) 600-6438
- Fax+1 (302) 655-5049
- Websitehttps://www.in8bio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 41.92m | 317.00 | -- | 0.4817 | 93.15 | 0.3281 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Movano Inc | 0.00 | -29.28m | 43.24m | 30.00 | -- | 7.12 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Bright Green Corp | 0.00 | -13.13m | 43.36m | 5.00 | -- | 3.84 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 43.39m | 32.00 | -- | 2.58 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 43.49m | 176.00 | -- | 2.81 | -- | 1.50 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 43.73m | 23.00 | -- | -- | -- | 15.52 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 44.02m | 55.00 | -- | 1.48 | -- | 2.60 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 44.13m | -- | -- | 2.34 | -- | 270.07 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 44.90m | 31.00 | -- | 2.52 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 44.98m | 14.00 | -- | 0.945 | -- | 2.37 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 45.67m | 65.00 | -- | 0.5801 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 46.16m | 82.00 | -- | 0.4648 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 47.02m | 75.00 | -- | 0.5198 | -- | 1.97 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Carmell Corp | 0.00 | -16.88m | 47.27m | 9.00 | -- | 2.13 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 47.74m | 15.00 | -- | 8.35 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | 0.00 | -184.22 | -- | -507.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.92 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to IN8BIO, Inc.'s reporting currency: US Dollar USD
28.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Dec 2023 | 4.10m | 9.47% |
| Transcend Partners LLCas of 13 Dec 2023 | 3.22m | 7.44% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.42m | 3.29% |
| Ensign Peak Advisors, Inc.as of 31 Dec 2023 | 1.12m | 2.58% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 819.67k | 1.89% |
| 683 Capital Management LLCas of 31 Dec 2023 | 614.75k | 1.42% |
| Sigma Planning Corp.as of 31 Mar 2024 | 515.08k | 1.19% |
| Voss Capital LLCas of 31 Dec 2023 | 341.21k | 0.79% |
| Geode Capital Management LLCas of 31 Dec 2023 | 199.42k | 0.46% |
| Stonegate Investment Group LLCas of 31 Mar 2024 | 180.00k | 0.42% |
More ▼
Data from 13 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
